- Fee assured
- Awaiting verification
- Breast specialist
- Breast surgery
- Breast specialist
Oliver Young undertook his undergraduate medical training at the University of Edinburgh qualifying in 1999. During his basic surgical training he also worked in Northampton and Christchurch, New Zealand. His subsequent surgical training was in Edinburgh with placements in both Dundee and Glasgow. He undertook two years of post graduate research at the Edinburgh Breast Unit under the supervision of Professor Mike Dixon. He has been a consultant in the Edinburgh Breast Unit since 2011 where he is now Clinical Director and works with a team of seven other consultants collectively treating over 900 new breast cancers annually. He manages a significant number of new cancers detected via the Scottish Breast Screening Programme. He has a very keen interest in neoadjuvant endocrine therapy and subsequent breast conservation surgery employing both well-established and novel oncoplastic techniques. He works very closely with other disciplines including pathology, radiology, oncology and clinical genetics. He currently chairs the Quality Improvement Team for the breast unit and has a keen interest in the safe streamlining and improvement of patient care pathways.
Areas of interest
Benign breast disease; Breast Cancer; Specialist interest in oncoplastic breast surgery; Family history advice and management of high risk patients.
- Secretary to Mr Oliver Young
- Spire Murrayfield Hospital Edinburgh 122 Corstorphine Road EDINBURGH EH12 6UD
- 0131 316 2548
Anaesthetists worked with
Current NHS consultant posts held
Consultant Breast Surgeon in Edinburgh Breast Unit since 2011. Currently Clinical Lead.
I have been involved in several trials looking at the biological effects on breast cancers of well established and novel agents in short pre-operative studies.
(Additional) Languages spoken
1. Current Practices in Breast Conservation Surgery: Results of a Questionnaire. PMID: 17346402
2. Surgical Issues Surrounding use of Aromatase Inhibitors. PMID: 16023854
3. Oestrogen-independent Cell Proliferation Occurs in the Majority of Oestrogen Receptor-Positive (ER+) / HER2 Gene-amplified Primary Breast Cancers: Evidence from a Combined Analysis of two Independent Neoadjuvant Letrozole Studies. PMID: 16754938
4. Src inhibitors in early breast cancer: a methodology, feasibility and variability study
5. Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer. PMID: 18083023
6. DCIS and aromatase inhibitors.PMID: 17604618
7. Molecular response to aromatase inhibitor treatment in primary breast cancer. PMID: 17555561
8. A randomised study of the effects of letrozole and anastrozole on oestrogen
receptor positive breast cancers in postmenopausal women. PMID: 18438705
9. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.PMID: 18375896
10. Increase in response rate by prolonged treatment with neoadjuvant letrozole. PMID: 18264759
11. The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study. PMID: 20941539
12. Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability.PMID: 20821047
13. Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial. PMID: 20179229
14. A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer. PMID: 19941160
- MBChB Edinburgh University Medical School 1999
Reference number 4610614
- Spire Murrayfield Hospital Edinburgh, EH12 6UD
- 17:00 - 20:00
- 0131 334 0363
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.
In the event of an urgent query following treatment, Bupa members should use the following contact details
0131 334 0363